Furthermore, we observed that lower expression levels of YBX3 were associated with improved clinical outcomes for ICB therapy (PDL1 or PD1) in bladder cancer and glioblastomas and consequently longer survival times (Supplementary Figure S1–5B, upper row). The gene discussed is CD274; the disease is urinary bladder cancer.